Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Key PointsEli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.